| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/23/2005 | CN1585767A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585766A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585765A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585764A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585749A Cannabinoid receptor ligands |
| 02/23/2005 | CN1585748A NK1 antagonists |
| 02/23/2005 | CN1585747A Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 |
| 02/23/2005 | CN1585742A Aryl aniline beta-2 adrenergic receptor agonists |
| 02/23/2005 | CN1585648A Enamel matrix protein compositions for modulating immune response |
| 02/23/2005 | CN1585646A Strontium compound for treatment of sub-dermal soft tissue pain |
| 02/23/2005 | CN1585641A Hydrazono-malonitriles |
| 02/23/2005 | CN1585634A Pharmaceutical composition comprising an adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor |
| 02/23/2005 | CN1585633A Phenethanolamine derivatives for treatment of respiratory diseases |
| 02/23/2005 | CN1585627A Microfabricated nanopore device for sustained release of therapeutic agent |
| 02/23/2005 | CN1583173A Serial medicines for hypertension and method for research, application and production |
| 02/23/2005 | CN1583172A Multifunctional liquid for clean therapy of nasal cavity and sinuses |
| 02/23/2005 | CN1190198C Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs activated T-lymphocytes |
| 02/23/2005 | CN1190187C Solid state solutions and dispersions of poorly water soluble drugs |
| 02/22/2005 | US6858714 Cyclic GMP phosphodiesterase |
| 02/22/2005 | US6858647 Administering retinoid such as, 6-(3-(1-Adamantyl)-4-methoxy-5-hydroxyphenyl)-2-naphthoic acid benzoic acid for therapy of and prophylaxis of bacterial infection |
| 02/22/2005 | US6858615 Phenyl guanidine sodium channel blockers |
| 02/22/2005 | US6858607 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/22/2005 | US6858598 Administering N-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phenyl)sulfonyl)-3 -thiomorpholinecarboxamide and an antineoplastic agent selected from irinotecan and topotecan and a combination thereof for therapy of lung cancer |
| 02/22/2005 | US6858593 Composition in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline composition is of space group P212121 having unit cell dimensions of about 7. 6+-0.6 Angstrom , 12.7+-0.7 Angstrom , |
| 02/22/2005 | US6858588 Nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from moringa oleifera |
| 02/22/2005 | US6858576 Methods for regulating gastrointestinal motility |
| 02/22/2005 | US6858420 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/22/2005 | US6858203 Treating of hyperphosphatemia by ingesting a ion exchanging resin comprising an allyl addition polymer having an amine salt or quaternary amine functional group; side effect reduction |
| 02/22/2005 | CA2236256C A pharmaceutical composition for the treatment of autoimmune diseases |
| 02/22/2005 | CA2220434C The use of epidermal growth factor as a gastrointestinal therapeutic agent |
| 02/20/2005 | CA2437709A1 Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events |
| 02/17/2005 | WO2005014856A1 Sensitivity test to predict efficacy of anti-cancer therapies |
| 02/17/2005 | WO2005014777A2 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 02/17/2005 | WO2005014776A2 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 02/17/2005 | WO2005014607A2 Antisense modulation of stearoyl-coa desaturase expression |
| 02/17/2005 | WO2005014600A1 Antagonists of mcp-1 function and methods of use thereof |
| 02/17/2005 | WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 02/17/2005 | WO2005014572A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005014045A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | WO2005014044A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | WO2005014043A1 Chlorthalidone combinations |
| 02/17/2005 | WO2005014034A1 Stabilized formulation of parathyroid hormone |
| 02/17/2005 | WO2005014013A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | WO2005014004A1 Combinations comprising staurosporines |
| 02/17/2005 | WO2005014002A1 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| 02/17/2005 | WO2005013994A1 Medicaments for inhalation comprising anticholinergics and a betamimetic |
| 02/17/2005 | WO2005013993A1 Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| 02/17/2005 | WO2005013986A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005013983A1 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/17/2005 | WO2005013980A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions. |
| 02/17/2005 | WO2005013969A1 Antipsychotic agent with socializing properties |
| 02/17/2005 | WO2005013967A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | WO2005013962A1 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/17/2005 | WO2005013961A1 Combination therapy for treatment of cognitive disorders or psychoses |
| 02/17/2005 | WO2005013958A1 Histone deacetylase inhibitors as immunosuppressants |
| 02/17/2005 | WO2005013957A2 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | WO2005013956A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | WO2005013945A2 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | WO2005013940A1 Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
| 02/17/2005 | WO2005013900A2 Method and composition for treating peridontal disease |
| 02/17/2005 | WO2005013691A1 Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| 02/17/2005 | WO2004103407A3 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 02/17/2005 | WO2004103358A3 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 02/17/2005 | WO2004092115A3 Hydroxamates as therapeutic agents |
| 02/17/2005 | WO2004091592A3 Methods and compositions to treat myocardial conditions |
| 02/17/2005 | WO2004089351A3 Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
| 02/17/2005 | WO2004063330A3 (2-carboxamido) (3-amino) thiophene compounds |
| 02/17/2005 | WO2004002999A8 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 02/17/2005 | WO2003025131A3 Protein modification and maintenance molecules |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050038415 Method and apparatus for the treatment of obesity |
| 02/17/2005 | US20050038126 Administering mammal a bicyclo [3.2.1]octan in a double ring system having kaurene structure such as steviol, isosteviol and stevioside; synergistic mixture with soy protein, and/or fiber and/or isoflavone |
| 02/17/2005 | US20050038122 Phenyl naphthol ligands for thyroid hormone receptor |
| 02/17/2005 | US20050038113 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 02/17/2005 | US20050038111 4'-cyano- alpha ', alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole); preventing side effect; bioavailability; storage stability; prostate cancer |
| 02/17/2005 | US20050038108 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency |
| 02/17/2005 | US20050038102 cardiovascular disease or a cerebrovascular disease; pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome |
| 02/17/2005 | US20050038083 Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias |
| 02/17/2005 | US20050038062 Methods and materials for the treatment of pain comprising opioid antagonists |
| 02/17/2005 | US20050038046 Synergistic enhancement of cognitive ability |
| 02/17/2005 | US20050038044 For drug resistance disease; side effect reduction; antiinflammatory agents; autoimmune disease |
| 02/17/2005 | US20050038029 Transferring, releasing nitric oxide; side effect reduction; using a compound containing nitrosos group |
| 02/17/2005 | US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 02/17/2005 | US20050038019 Hydroxy substituted amides for the treatment of alzheimer's disease |
| 02/17/2005 | US20050038018 Meloxicam compositions |
| 02/17/2005 | US20050038015 Partial dopamine-D 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
| 02/17/2005 | US20050038008 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 02/17/2005 | US20050038007 Adjust solubility; immediate release of HMG-COA reductase inhibitor and sustained release of cholesteryl ester transfer protein; anticholesterol agents |
| 02/17/2005 | US20050038003 Synergistic mixture; myocardial infarction; cardiovascular disorders |
| 02/17/2005 | US20050037996 Controlling temperature and pH while complexing |
| 02/17/2005 | US20050037990 Disubstituted 7,9-guanines halides as telomerase inhibitors |
| 02/17/2005 | US20050037984 Administering protein kinase C activator |
| 02/17/2005 | US20050037976 Hematopoietic stimulation |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037495 Human CNS cell lines and methods of use therefor |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037449 Agent for controlling circadian rhythm disorder |
| 02/17/2005 | US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/17/2005 | US20050037092 Vascularization therapy by highly concentrated carbonated warm water bath |